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Summary: Background: Peripheral artery disease (PAD) of the lower limbs is a common 
condition with considerable global burden. Some country-specific studies suggest low levels 
of public awareness. To our knowledge public awareness of PAD has never been assessed 
simultaneously in several countries worldwide. Patients and Methods: This was an 
international, general public, internet-based quantitative survey assessing vascular health 
and disease understanding. Questionnaires included 23 closed-ended multiple-choice, Likert 
scale and binary choice questions. Data were collected from 9,098 survey respondents from 
nine countries in Europe, North and Latin America during May-June 2018. Results: Overall, 
familiarity with PAD was low (57% of respondents were ‘not at all familiar’, and 9% were 
‘moderately’ or ‘very familiar’). Knowledge about PAD health consequences was limited, with 
55% of all respondents not being aware of limb consequences of PAD. There were 
disparities in PAD familiarity levels between countries; highest levels of self-reported 
awareness were in Germany and Poland where 13% reported to be ‘very’ or ‘moderately’ 
familiar with PAD, and lowest in Scandinavian countries (5%, 3% and 2% of respondents in 
Norway, Sweden and Denmark, respectively). There were disparities in awareness 
according to age. Respondents aged 25–34 were most familiar with PAD, with 12% stating 
that they were ‘moderately’ or ‘very’ familiar with the condition, whereas those aged 18–24 
were the least familiar with PAD (7% ‘moderately’ or ‘very’ familiar with PAD). In the 45–54, 
55–64 and 65+ age groups, 9% said they were ‘moderately’ or ‘very’ familiar with the term. 
There was no important gender-based difference in PAD familiarity. Conclusions: On an 
international level, public self-reported PAD awareness is low, even though PAD is a 
common condition with considerable burden. Campaigns to increase PAD awareness are 
needed to reduce delays in diagnosis and to motivate people to control PAD risk factors. 
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Introduction 
Peripheral artery disease (PAD), also termed lower extremity arterial disease (LEAD) (1) is a 
cardiovascular condition attributable to atherosclerotic disease (2). The condition is on the 
rise globally (2, 3) and exerts a significant burden on patients and healthcare systems (3). Its 
presentation ranges from the asymptomatic stage to pain at exertion, at rest, or to the 
occurrence of tissue loss. If not treated adequately, especially in cases of severe 
presentation, it may cause gangrene and necrosis resulting in limb amputation with 
substantial quality of life and socioeconomic burden. Patients with PAD, even though 
asymptomatic, are at increased risk of cardiovascular events and mortality (2). 
 
Importantly, patients with PAD are still undertreated and treatment varies between countries. 
According to the 2016-17 Quality and Outcomes Framework in England, 89% of people with 
PAD are prescribed an antiplatelet agent  (4, 5). In the national SWEDVASC registry authors 
showed that best medical therapy, defined as any antiplatelet or anticoagulant therapy along 
with statins, was offered to 65% of patients with claudication, and only to 45% of patients 
with critical limb ischaemia (6).  
 
The prevalence of PAD has increased by 17% since 2010 when 202 million individuals were 
affected, illustrating the extent of PAD burden as a global public health problem (3). In 2015 
nearly 237 million people were living with PAD worldwide with just under 64 million (27%) 
affected in high-income countries (HIC) (3). PAD prevalence was highest in Europe (7.99%, 
95% confidence intervals (CI) 5.10–13.41) and lowest across Africa (4.06%, 95% CI 2.90–
5.91) (3). In both HIC and low-income or middle-income countries (LMIC), the prevalence of 
PAD increased across all age groups from 25 to 69 years in 2015 (3). A slightly higher 
prevalence of PAD was identified in women than in men up to 75 years of age in HIC, 
however, in LMIC there were minimum gender differences (3). Smoking, diabetes, 
hypertension, and hypercholesterolaemia were also identified as major risk factors for PAD 
(3). The age-standardized disability-adjusted life year (DALY) rate (per 100,000) for PAD 
was 19.3 (14.4 to 26.3) in 2016 (7). 
 
Despite these figures, PAD is currently underdiagnosed, and clinical awareness and interest 
in the condition appears to be lower (8),(9) compared to coronary artery disease (CAD) (10). 
Furthermore, awareness of symptoms associated with PAD, including intermittent 
claudication, critical limb ischaemia, and cardiovascular and limb-related outcomes, are 
inadequate (8). There is an urgent need to increase understanding and public awareness 
about PAD (11). 
 
In this report, we present outcomes from an international survey designed to assess current 
levels of understanding of vascular health and disease among the public worldwide. In 
particular, this survey assessed awareness of PAD compared to CAD, the extent of 
recognition of PAD symptoms, PAD-related risk factors, complications and consequences.  
 
Materials and Methods 
An internet-based quantitative survey was developed to assess current levels of 
understanding of vascular health and disease among the public. Twenty-three closed-ended 
multiple choice, Likert scale and binary choice questions were asked throughout the 
questionnaire, to assess general awareness of PAD, CAD and the connection between 
vascular health and PAD/CAD.   
 
Respondents were asked if they had a family history of vascular disease and if they were 
aware of the risk factors involved and preventative measures that could be taken.  Moreover, 
participants were asked about their knowledge of symptoms and outcomes for each of both 
conditions. For descriptions of symptoms/outcomes, both true and false response options 
were offered to test the respondents’ knowledge.  Respondents were not permitted to return 
to completed questions or correct their answers in order to prevent any bias. The survey 
questionnaire is presented in Table SI, and additional results in Table SI through Table SX. 
 
The survey data collection and fieldwork were carried out by the research agency Vitreous 
World according to British Healthcare Business Intelligence Association (BHBIA) Legal and 
Ethical Guidelines as well as guidelines established by the UK’s Market Research Society 
(MRS). The survey was fielded among participants from the public aged over 18 years who 
were recruited from online panels that met required BHBIA and MRS standards for data 
collection. The survey was translated into individual languages for countries participating in 
the survey. 
 
The data collection and fieldwork were completed between May 18, 2018, and June 13, 
2018, across nine countries: UK, Germany, Sweden, Norway, Denmark, Poland, Canada, 
Mexico and Brazil. A nationally representative sample of data was collected in each country, 
utilizing quotas across age and gender. Demographic information of respondents including 
country of residence, age and gender was collected. The social classification of respondents 
was not included during data collection. Respondents were included to provide a 50/50 
gender split and were evenly split among the six age groups. Once these quotas were 
reached in each country, the survey was closed. In order to have unbiased results, 
healthcare professionals (e.g. physicians, nurses, pharmacists, researchers in biology) were 
systematically excluded from the survey. 
 
Following this initial phase, eligible respondents were then asked to complete the full 
standardized questionnaire (see supplements, Table SI). Completion of the questionnaire 
took approximately 10 minutes. The questionnaire included 23 closed-ended multiple choice, 
Likert scale and binary choice questions. 
 
Results 
A total of 9,089 participants responded to the survey with 1,010 responses from each of the 
nine participating countries. Summary demographics of survey respondents are shown in 
Table I.  
 
Familiarity With PAD 
Among all respondents, 57% (n=5,222) declared they were ‘not at all familiar’ with PAD 
(Fig.1). Nine percent (n=853) stated they were ‘moderately’ or ‘very familiar’ with PAD. In 
Europe, the countries with the highest levels of familiarity with PAD were Germany and 
Poland, where 13% (n=133/1,010) of people in both countries claimed to be ‘very’ or 
‘moderately’ familiar with the condition. The lowest levels of disease familiarity were reported 
from the Scandinavian countries, with 5% (n=47), 3% (n=34) and 2% (n=19) of respondents 
in Norway, Sweden and Denmark, respectively, reporting to be ‘moderately’ or ‘very’ familiar 
with PAD.  
 
Disparities in awareness were observed according to age. Twelve percent of respondents 
aged 25–34 years stated that they were ‘moderately’ or ‘very’ familiar with PAD, compared 
with 7% of those aged 18–24 years. In the 45–54, 55–64 and 65+ age groups, 9% of 
respondents said they were ‘moderately’ or ‘very’ familiar with PAD. Among respondents 
aged 18–24 years, 79% stated that they were ‘slightly’ or ‘not at all’ familiar with PAD, 
followed by 78% in those aged 65+ years. 
 
Knowledge of Body Parts Affected by PAD  
Thirty-four percent (n=3,085) of all respondents definitely associated PAD with the arms and 
legs. Respondents from Scandinavian countries and the UK showed the lowest recognition, 
with more than two thirds of respondents either not associating arms and legs with PAD or 
being unsure about the association (Norway 80%, n=813; Denmark 78%, n=792; Sweden 
74%, n=749; UK 71%, n=719), as shown in Table SII. Respondents from Germany showed 
the highest recognition with 47% (n=473) definitely considering the arms and legs to be 
associated with PAD. In general, the heart was reported to be more frequently (48%; 
n=4,379) associated with PAD than arms and legs. 
 
Among respondents who self reported to be ‘very’ or ‘moderately‘ familiar with PAD, most 
identified heart (25%) and arms and legs (22%) as body parts associated with PAD (Fig. 2). 
Individual country responses, where there is some variability in knowledge of body parts 
affected, are shown in the Electronic Supplementary Material, 2. 
 
Knowledge of PAD Signs and Symptoms 
Overall, 26% (n=2,338) of respondents definitely considered lower extremity ulcers as a 
symptom of PAD. The percentage was higher in respondents that self-reported as being 
‘very familiar’ (55%) or ‘moderately familiar’ (50%) with PAD. 
 
Less than half of the respondents in Poland (42%, n=428) considered leg weakness and 
numbness a symptom of PAD.  Awareness of these symptoms was even lower in Denmark, 
Sweden, Norway and the UK. In Norway, only 10% (n=98) definitely considered cramping 
(claudication) a symptom of PAD.  
 
The survey also included symptoms that are not associated with PAD to test whether 
respondents could identify those that are linked to the condition. Fever was identified as a 
direct PAD symptom by 11% (n=978) of all respondents. Respondents’ knowledge of PAD 
symptoms is shown in Fig. 3. 
 
Awareness of the Risks Associated With PAD 
Among all respondents, 55% (n=4,959) did not consider ‘death of the tissue in the leg 
caused by a lack of blood flow’ as a consequence of PAD. The lack of awareness of this 
PAD associated risk was highest in respondents from Norway (81%; n=821). 
 
Almost half of all respondents (48%, n=4,324) considered ‘a complete loss of feeling in the 
leg due to a lack of blood flow’ as an outcome associated with PAD. Additionally, 47% 
(n=4,278) of all respondents stated that ‘reduced movement of the leg due to a lack of blood 
flow’ is an outcome of PAD. Awareness levels of the risks associated with PAD are shown in 
Fig. 4.  
Awareness that PAD Commonly Occurs in Those Who Have CAD 
Overall, 72% (n=6,507) of all respondents were unaware that PAD occurs more commonly in 
those who have CAD (Fig.5). The lowest proportion of people acknowledging this 
comorbidity occurrence was in Denmark (16%, n=162), the highest in Poland (47%, n=478).  
 
Discussion 
To our knowledge, this is the first international survey on public awareness of PAD. The 
findings from this international survey highlight a general lack of public awareness and 
knowledge about PAD. Awareness of its symptoms, future risks and how it affects the body 
were poor. Despite being the third leading cause of atherosclerotic cardiovascular morbidity 
(12), over half of all respondents admitted that they were ‘not at all familiar’ with PAD. 
Furthermore, 55% of all survey respondents were not aware that a key consequence of PAD 
is tissue death in the legs caused by a lack of blood flow. Overall, there was limited 
knowledge of which parts of the body are affected by PAD, and of the vascular system in 
general. 
 
The lack of PAD awareness among the general public identified in this international survey is 
consistent with the results of a study conducted in Sri Lanka on awareness of PAD among 
the 40- to 74-year-old population (n=2912).  The survey showed that 4.1% of participants 
were aware of PAD, significantly lower than awareness of other cardiovascular diseases 
such as cerebral vascular accidents (67.3%) and myocardial infarction (57.6%) which was 
statistically significant (p<0.001).  The authors concluded that a comprehensive PAD 
awareness program to cover risk factors, consequences, and prevention strategies is 
needed to enhance public awareness of PAD. (13) 
 
PAD is common in patients with CAD with a prevalence of 22–42% (14). Awareness of this 
association is important because among patients with CAD, those with comorbid PAD have 
worse cardiovascular outcomes than patients with CAD alone (14). However, the survey 
results showed that almost three quarters of all respondents were unaware that PAD 
commonly occurs in those who have CAD. In contrast to CAD, of which 37% of the 
respondents were “not at all familiar”, this answer was given in 57% for PAD, and 87% 
considered CAD a more serious health condition than PAD, illustrating a lack of awareness 
with regards to PAD compared to CAD.  
 
Of note, the 9% of familiarity with PAD among responders (“moderately” or “very familiar”) is 
approximately on the level of overall prevalence of PAD (3). While we cannot infer it from the 
data, it may be that familiarity with PAD is stronger among people with direct experience with 
PAD themselves as patients, and among their closest relatives. Accordingly, the space for 
public awareness among an international population seems to be very broad here.    
 
Over the next decade, the burden of PAD worldwide is expected to grow rapidly, driven 
mainly by population growth, ageing, increasing trend in conventional PAD cardiovascular 
risk factors, and changing demographics and lifestyles (12, 15). Given the key knowledge 
gap existing among the public, especially related to the impact of PAD, raising awareness is 
an essential step to address social and economic consequences of PAD, as well as to 
enable effective preventive and secondary preventive measures (12). 
 
The main goals of treatment in patients with PAD are to reduce cardiovascular risk and 
improve functional capacity. However, given the lack of awareness of PAD, undertreatment 
is an issue and needs to be addressed as a global health priority. This imperative was 
recognized by the European Society of Cardiology in association with the European Society 
for Vascular Surgery in their 2017 Guidelines on the Diagnosis and Treatment of Peripheral 
Arterial Diseases, as well as by the European Society of Vascular Medicine in their 2019 
guidelines (1) (16).  
 
Strategies to increase awareness need to be implemented in the community and in primary, 
secondary and tertiary care settings. PAD education among the public and healthcare 
practitioners should be developed in each country. This need was highlighted by a recent 
survey conducted in the North-East of England, United Kingdom, where factors were 
identified that impact on PAD diagnosis.  These include the attitude of primary care health 
professionals to PAD, problems accessing diagnostic tests, and delays in patients seeking 
medical advice from their general practitioner due to a lack of understanding about PAD and 
its associated symptoms (17). A recent large French survey identified substantial differences 
in GP knowledge with broad knowledge about transient ischemic attacks, some knowledge 
on stable angina and very little knowledge about diagnosis and management of intermittent 
claudication (18). Public campaigns raising awareness about PAD and its risk factors are 
useful in informing and motivating people to act to prevent the disease and control its risk 
factors (17).  
 
Limitations 
Among limitations of this survey questionnaire, its online nature should be noted since people 
without internet access were unable to participate. Broadband access has been described as 
a “super-determinant” of health, and internet use associated with health literacy in older age 
(19, 20). Therefore, our findings may, if anything, overestimate true levels of understanding 
among the general population, since PAD knowledge may be even lower than reported here 
in people with no internet access, and in older age groups. Respondents with internet access 
were able to answer the questionnaire via a personal computer or mobile device, and all 
respondent quotas by country and demographic were met without any survey adaptations. 
However, since the participants were recruited from online panels and respondents were 
provided with an incentive for their participation, the study group cannot be considered as 
representative for each participating country. 
 
Also, it has been reported that the awareness about risk factors of PAD may be influenced 
by the individual’s own risk factors (21).  In our survey, we have not asked for personal 
health conditions and habits, so we cannot assess the influence of personal health 
background on the awareness of PAD and its risk factors.   
 
Countries where a lower prevalence of PAD and CAD is observed, such as Italy, Spain, and 
Greece, were not included in this survey.  While this is a multi-country survey, a limitation 
lies in the number of countries selected to participate and the geographical spread.  For 
example, Africa and Australasia are not represented in this survey. 
 
A further limitation was the language used around PAD, CAD and vascular health, with 
varying terminology used per country. We cannot exclude that an imperfect choice of the 
words used to translate PAD into common languages may have negatively influenced the 
understanding of the questions. Specifically, in the Nordic Countries, the more common lay 
man wording for PAD was not used in the questionnaire. This may partially explain the low 
level of awareness recorded in those countries. However, we do not think these would 
substantially alter our general conclusions.  
 
Overall, a consistent survey methodology was used across all countries.  Any differences in 
gender or age sampling per country is purely random and may be due to recruitment 
challenges, resulting in some countries having younger female respondents in samples than 
other countries. Similarly, the responses for older age groups above 65 years, were too few 
to analyse by country, perhaps reflecting lower internet use in these age groups (20). 
Despite the inherent cross-country limitations due to culture, language, and internet access, 
the dataset has enabled an international description of the general awareness of PAD. 
 
Conclusions 
The results of this international, public, self-reporting survey indicate that key knowledge 
gaps exist in relation to PAD, varying across countries. This demonstrates the need to 
increase public and patient awareness of the importance of reducing lifestyle-associated risk 
factors as well as promptly recognizing PAD symptoms, thus allowing for appropriate 
diagnostic workup and therapeutic management. Death rates from PAD are expected to rise 
due to the aging of the population over the next decade, and it is important to inform people 
of the dangers associated with this. 
 
These findings can assist in formulating educational programs aimed at the public, including 
patients with a diagnosis of PAD or CAD, to assist in driving preventative health awareness 
campaigns.  As such, this paper can be used in communicating with patient advocacy 
groups, medical organizations, and governmental health departments, to provide evidence 
on the need for improved awareness about PAD and the potential lifelong implications of 
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Table I. Demographics of survey respondents by gender, age and country* 
 Total 
Age (years) 
18-24 25-34 35-44 45-54 55-64 65+ 
No. 
Respondents 
9089 1197 1696 1673 1656 1396 1471 
 
Male 
       
49% 34% 42% 47% 55% 57% 59% 
 
Female 
       





Mexico Poland Germany Brazil Canada UK Norway Sweden Denmark 
No. 
Respondents 
9089 1010 1010 1010 1010 1009 1010 1010 1010 1010 
 
Male 
          
49% 50% 48% 51% 48% 47% 49% 51% 50% 49% 
 
Female 
          




          
13% 19% 12% 11% 18% 12% 11% 13% 12% 10% 
 
25-34 
          
19% 23% 20% 16% 26% 15% 17% 18% 16% 16% 
 
35-44 
          
18% 19% 16% 19% 20% 16% 20% 19% 17% 19% 
 
45-54 
          
18% 20% 17% 22% 16% 20% 16% 20% 16% 18% 
 
55-64 
          
15% 13% 17% 15% 11% 18% 15% 16% 15% 18% 
 
65+ 
          
16% 6% 17% 17% 10% 19% 21% 14% 24% 19% 
* A total 9,090 respondents were included, but one respondent from Canada did not meet quality 
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Figure 1. Self-reported awareness of PAD among survey respondents in response to the 
question,  









Figure 2. Knowledge of body parts affected by PAD in response to the question  
‘Which of the following parts of the body would you definitely associate with PAD:  
arms and legs, heart, kidneys, lungs, brain, stomach’ among respondents whose  
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Figure 3. Knowledge of PAD symptoms among respondents in response to the question, 








Figure 4. Awareness of the risks associated with PAD among respondents when asked the 
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PAD if left untreated: a complete loss of feeling in the leg due to a lack of blood flow, death 
of the tissue in the leg due to a lack of blood flow, infection caused by toxins in the blood, 
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Figure 5. Rates of responses to the question: ‘Peripheral artery disease (PAD) commonly 
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